Reishi (Ganoderma lucidum)
= rapamycin, ganoderic acid A extended healthspan in preclinical models as effectively as the anti-aging drug rapamycin
A 2025 Nature Communications study identified ganoderic acid A from reishi as a senotherapeutic that extends healthspan comparably to rapamycin. A 2021 study found reishi triterpenoids preserved telomere length in aging mouse brains.
Chen et al., Nat Commun, 2025; Zeng et al., Front Aging Neurosci, 2021
Zeng 2021
only published study directly measuring telomere length in reishi-treated aging mice
0 human trials
measuring reishi's effect on telomere length in people
Triterpenoids
the compound class responsible for the telomere-preserving effect in Zeng 2021
Chen et al., Nat Commun, 2025; Zeng et al., Front Aging Neurosci, 2021
View as image ↗Every cell in the body carries a clock. Telomeres are the protective caps on the ends of chromosomes, and they shorten with each cell division. When they become critically short, cells stop dividing, a state called replicative senescence. The pace of telomere shortening is one of the most studied biological clocks in aging research, and interventions that slow or reverse it are the focus of significant scientific effort.
Reishi mushroom (Ganoderma lucidum) is a subject in this research, though with one important caveat: the evidence is almost entirely preclinical. One 2021 animal study directly measured telomere length in reishi-treated aging brains.[1] No human clinical trial has measured this endpoint. This article covers what that study found, what related research suggests about the mechanism, and where the evidence currently stands. For the full science of what reishi is, see What Is Reishi Mushroom?.
Key Takeaways
- A 2021 study found long-term reishi triterpenoid administration preserved telomere length in aging mouse brains while also mitigating cognitive decline and regulating sphingolipid metabolism.
- A 2008 study found Ganoderma extract modulates telomerase activity in cancer cells, providing early evidence for a telomere-related mechanism.
- A 2025 Nature Communications study found ganoderic acid A (GA-A) prevents cellular senescence and extends healthspan in preclinical models comparably to rapamycin, connecting reishi to the molecular biology of cellular aging.
- Peng 2021 found reishi extract extends C. elegans lifespan through autophagy activation, a pathway mechanistically linked to telomere length maintenance.
- There are no human clinical trials measuring reishi's effect on telomere length. All current evidence is from animal and cell models.
- The mechanism linking reishi triterpenoids to telomere preservation appears to involve sphingolipid metabolism regulation and autophagy, not direct telomerase activation.
Why Telomere Length Matters for Aging
Telomeres are sequences of repetitive DNA (TTAGGG in humans) that cap the ends of chromosomes. They function like the plastic tips on shoelaces, preventing chromosomes from fraying or fusing with each other. Each time a cell divides, its telomeres shorten slightly because the DNA replication machinery cannot fully copy the ends of linear chromosomes.
Cells with critically short telomeres typically stop dividing permanently. This replicative senescence can be protective in some contexts (preventing cells with damaged DNA from proliferating) but accumulative in others. When large numbers of cells in a tissue become senescent, they secrete inflammatory molecules (a phenomenon called SASP, the senescence-associated secretory phenotype) that damage neighboring healthy cells and accelerate tissue aging.
The enzyme telomerase can rebuild telomere length by adding DNA sequences back to chromosome ends, but most adult somatic cells have low telomerase activity. Stem cells maintain higher telomerase activity and retain their ability to divide more robustly. Cancer cells often reactivate telomerase, which is part of how they achieve unlimited division.
Research interest in telomere-targeting interventions is high because telomere length has been correlated with biological age, immune function, and risk of age-related disease in epidemiological studies. Whether specific compounds can meaningfully slow telomere attrition or activate telomerase in normal cells is an active area of investigation.
Zeng 2021: The Only Published Measurement of Reishi's Effect on Telomere Length
The 2021 study by Zeng et al. published in Frontiers in Aging Neuroscience is the only published study that has directly measured telomere length as an outcome of reishi triterpenoid administration.[1] The study administered Ganoderma lucidum triterpenoids long-term to aging mice and assessed effects on brain physiology, cognitive function, and molecular aging markers.
The headline findings: long-term triterpenoid administration preserved telomere length in aging mouse brain tissue. In untreated aging mice, telomere length in brain cells shortened over the study period, as expected with normal aging. In mice receiving the triterpenoid preparation, telomere length was significantly better preserved.
The study also found effects on sphingolipid metabolism. Sphingolipids are a class of bioactive lipids in cell membranes, and their metabolism becomes dysregulated with aging in ways that affect cell survival signaling, membrane integrity, and neurodegeneration risk. Reishi triterpenoids normalized key aspects of sphingolipid metabolism in the aging mouse brains. The study also documented enhanced autophagy, the cellular recycling process that becomes impaired with age.
Cognitive decline was mitigated alongside the molecular changes. Treated aging mice showed better performance on cognitive tasks compared to untreated aging mice, suggesting the molecular preservation effects had functional consequences.
This is a well-designed animal study with mechanistically interesting findings. It is not a human trial. Mouse brain biology differs from human brain biology in important ways. The dose, the specific triterpenoid preparation, and the duration tested may not map directly to any commercially available supplement. And the study's results have not been independently replicated in a separate laboratory.
What Zeng 2021 provides is the only direct measurement anyone has published of a reishi compound's effect on telomere length in a living organism. For researchers tracking this field, it is the foundational reference point.
Zeng et al. (2021) · Frontiers in Aging Neuroscience
- Population
- Normal aging mice, plus APP/PS1 and 3×Tg-AD Alzheimer's disease mouse models
- Intervention
- Long-term oral administration of triterpenoids of Ganoderma lucidum (TGL)
- Comparator
- Untreated aging mice
- Finding
- TGL mitigated age-associated brain decline and cognitive impairment. The proposed mechanism involved regulating sphingolipid metabolism, prolonging telomere length, and enhancing autophagy. The authors identified ganoderic acid A as a likely active constituent in the Alzheimer's models.
preliminary A well-designed animal study and the field's only direct telomere-length measurement for a reishi compound — but mouse brain biology, an unspecified supplement-equivalent dose, and the absence of independent replication mean it cannot be extrapolated to people.
Zeng et al., Frontiers in Aging Neuroscience, 2021 (PMID 34025387)
Telomerase Modulation: Earlier Evidence From 2008
The Zeng 2021 finding builds on earlier evidence connecting Ganoderma to telomere biology. In 2008, Yuen et al. published a study showing that Ganoderma extract triggers telomerase-associated apoptotic events in premalignant human urothelial (bladder) cells.[2]
The context here matters. This was a cancer cell study, testing how Ganoderma affects telomerase in tumor cells, not in healthy aging cells. In cancer cells, high telomerase activity is part of what gives them unlimited replicative potential. Reducing telomerase activity in cancer cells can contribute to apoptosis, which is one mechanism by which mushroom extracts can act against cancer.
The Yuen 2008 finding does not directly tell us whether reishi modulates telomerase in healthy aging cells in a lifespan-extending direction. The contexts are biologically different: you want to reduce telomerase in cancer cells and potentially preserve it in aging stem cells. What the study does establish is that Ganoderma compounds interact with the telomerase system, providing early mechanistic evidence that this is a biologically relevant connection rather than a speculative one.
The 13-year gap between Yuen 2008 and Zeng 2021 reflects the slow accumulation of evidence in this specific area of reishi research.
Ganoderic Acid A: Extending Healthspan Like Rapamycin
The most significant related finding in recent years comes from a 2025 study published in Nature Communications by Chen et al.[3] The study used high-content screening to identify compounds that prevent cellular senescence, and identified ganoderic acid A (GA-A), a triterpenoid found in reishi, as a potent senotherapeutic.
GA-A prevented senescence across a broad range of cell types by binding directly to TCOF1, a nucleolar protein involved in ribosome biogenesis. When TCOF1 function is maintained, ribosome homeostasis is preserved, and cells resist entering the senescent state. This is a specific molecular mechanism, not a vague antioxidant effect.
The healthspan extension data is what makes this finding exceptional. In C. elegans (the roundworm commonly used in aging research) and in mouse models, GA-A extended healthspan comparably to rapamycin. Rapamycin is the most studied pharmacological intervention in longevity biology, with consistent lifespan and healthspan extension across multiple organisms. A natural compound from a mushroom matching its efficacy in preclinical models is an unusual finding.
Healthspan is distinct from maximum lifespan. It refers to the period of life during which an organism remains healthy and functional. Extending healthspan while keeping maximum lifespan constant means animals are sick for a shorter proportion of their lives. Extending both is the larger goal.
The connection to telomere biology: cellular senescence and telomere attrition are linked. One primary trigger for senescence is telomere shortening reaching a critical threshold. If GA-A prevents senescence through a different route (ribosome homeostasis via TCOF1), it can act downstream of telomere shortening rather than by lengthening telomeres directly. This is mechanistically complementary to Zeng 2021's telomere preservation finding: both studies suggest reishi compounds slow cellular aging, via different points in the pathway.
For more on GA-A and the broader ganoderic acid compound family, see Ganoderic Acid A, B, and Beyond: Individual Compound Research. For how ganoderic acids fit within the broader triterpene profile of reishi, see Ganoderic Acids: The Unique Triterpenes in Reishi.
Autophagy: The Cellular Recycling Link to Telomere Biology
A 2021 study by Peng et al. published in Aging (Albany NY) found that Ganoderma lucidum extract extends C. elegans lifespan by activating autophagy through two canonical longevity pathways: DAF-16/FOXO and SKN-1/Nrf2.[5] This same effect was validated in human cell models, not just the worm.
Autophagy is the process by which cells dismantle and recycle damaged components: misfolded proteins, dysfunctional organelles, and other cellular debris. It declines with age, and this decline is one of the mechanisms driving age-related cellular dysfunction. Organisms with robust autophagy typically have longer and healthier lives.
The connection to telomere biology: autophagy protects telomere integrity through several mechanisms. It clears reactive oxygen species (ROS) that would otherwise attack and damage telomeric DNA. It maintains mitochondrial quality, and mitochondrial dysfunction accelerates telomere shortening. It also degrades damaged telomere-associated proteins that would otherwise accumulate.
Zeng 2021 documented enhanced autophagy alongside telomere preservation in the aging mouse brain study, suggesting these two effects may not be independent. A reishi triterpenoid preparation that activates autophagy would, through that mechanism, also create conditions more favorable to telomere preservation. Peng 2021 provides the autophagy activation data; Zeng 2021 shows the telomere preservation outcome.
A comprehensive 2017 review in Aging and Disease by Wang et al. positioned this constellation of effects within the broader framework of Ganoderma's anti-aging activity: telomere attrition, mitochondrial dysfunction, cellular senescence, and impaired autophagy are all recognized hallmarks of aging, and Ganoderma appears to have evidence at each of these intersection points.[4]
Mechanism Convergence
Four Mechanisms, Four Studies, One Direction of Travel
Reishi’s anti-aging signal is not a single telomere-lengthening pathway. It is four separate mechanisms — each documented in a different preclinical study, each acting at a different point in the aging process — that converge on the same outcome: slowed cellular aging and better-preserved telomeres. None of these has been measured in a human.
Telomere preservation
preclinicalLong-term reishi triterpenoids preserved telomere length in aging mouse brains and normalized sphingolipid metabolism
Zeng 2021 [1]
Telomerase modulation
preclinicalGanoderma extract altered telomerase activity in cancer cells — evidence the compounds interact with the telomerase system (context-dependent direction)
Yuen 2008 [2]
Senescence prevention
preclinicalGanoderic acid A bound TCOF1 to preserve ribosome homeostasis and block cells from entering senescence — downstream of the telomere clock
Chen 2025 [3]
Autophagy activation
preclinicalReishi extract activated DAF-16/FOXO and SKN-1/Nrf2 autophagy pathways in C. elegans and human cells, clearing debris that would otherwise damage telomeres
Peng 2021 [5]
Slowed cellular aging & preserved telomere length
Demonstrated in mice, worms, and human cells — never in a living person
How to read it: the strength of this picture is that four independent mechanisms point the same way — a 2017 review (Wang 2017) framed all four as recognized hallmarks of aging. The limit is that every box is preclinical. Convergent mechanisms raise plausibility; they do not substitute for a human outcome.
Sources: Zeng 2021 [1]; Yuen 2008 [2]; Chen 2025 [3]; Wang 2017 [4]; Peng 2021 [5]. Grouping is illustrative of mechanistic convergence, not quantitative effect sizes.
The picture that emerges is not a single telomere-lengthening pathway but several reishi mechanisms acting at different points in the aging process, each documented in a separate preclinical study, that together create conditions favoring telomere preservation.
For the cellular senescence angle and how reishi compounds may prevent and clear senescent cells, see Ganoderma lucidum and Cellular Senescence. For the broader anti-aging context, see Reishi and Longevity: Why It's Called the Mushroom of Immortality.
The Honest Picture: No Human Trial Has Measured Reishi and Telomere Length
No published human clinical trial has administered reishi and then measured telomere length as an endpoint. This is not a small caveat. The gap between animal/cell evidence and human clinical data is the largest uncertainty in this area.
- Cell & Lab Studiescompleted
Ganoderma triggers telomerase-associated apoptosis in premalignant human cells (Yuen 2008); ganoderic acid A prevents senescence via TCOF1 across cell types, with autophagy validated in human cells (Chen 2025; Peng 2021)
- Animal Studiescurrent
Reishi triterpenoids preserved telomere length and mitigated cognitive decline in aging mouse brains (Zeng 2021); GA-A and reishi extract extended healthspan/lifespan in mice and C. elegans (Chen 2025; Peng 2021). This is as far as the evidence reaches.
- Human Case Reports & Early Seriesmissing
No human case reports or early series measuring telomere or aging endpoints after reishi
- Small Human Trialsmissing
No human trial has administered reishi and measured telomere length — or any direct telomere endpoint — in people
- Large Randomized Trialsmissing
No dose-finding, bioavailability, or long-term outcome trials of reishi triterpenoids for telomere or aging endpoints in humans
- Meta-Analyses & Systematic Reviewsmissing
No human meta-analysis exists because no human telomere trials exist to pool
The evidence climbs from cell studies to animal studies and stops there — a 2017 review (Wang 2017) frames these preclinical findings within the recognized hallmarks of aging, but every rung from human case reports upward is empty. No human has ever had their telomere length measured after taking reishi. The claim is mechanistically plausible and preclinically supported, not clinically established.
Aggregate of Yuen 2008, Zeng 2021, Peng 2021, Chen 2025, and the Wang 2017 review
Telomere dynamics in humans are more complex than in mice or C. elegans. The relationship between supplement dosing, bioavailability of specific triterpenoid compounds, tissue distribution, and telomere effects in human tissues has not been characterized. The doses and preparation types used in the preclinical studies may not correspond to what is achievable with available supplements.
There are also important questions about whether preserving telomere length is the right target. Epidemiological studies show correlations between short telomeres and age-related disease, but correlation does not establish causation. Interventions that lengthen telomeres in cancer-prone individuals could theoretically increase cancer risk if telomere extension enables damaged cells to escape senescence. Telomere biology research is active precisely because these questions are not yet resolved.
Safety — telomere lengthening is not automatically desirable
ModerateMore telomere is not always better
Concern
Telomere maintenance is the same capability cancer cells exploit to divide without limit. In theory, an intervention that helps damaged or precancerous cells hold onto telomere length could help them escape the senescence that would otherwise stop them. The only reishi telomere data comes from healthy aging mouse brains, not from people, and not from anyone with elevated cancer risk. Note that the one human-cell reishi study on telomerase (Yuen 2008) drove telomerase-associated apoptosis in premalignant cells — the effect that matters depends entirely on the cell type and context.
What the research says
Do not treat 'preserves telomeres' as a reason to self-treat, and be especially cautious if you have a personal or family history of cancer. No reishi supplement has been shown to safely or beneficially change telomere length in humans.
Particularly relevant for: People with a personal or family history of cancer, or precancerous conditions
What to do
Discuss reishi supplementation with a physician if you have any cancer risk factors. This article is educational and is not medical advice.
Safety framing based on the cancer-context distinction in Yuen 2008 and the absence of any human reishi telomere trial
What the available evidence supports: reishi triterpenoids interact with telomere-related biology in animal models, and specific compounds like GA-A show promise as senotherapeutics in preclinical settings. The mechanistic picture is coherent and interesting. It does not yet include human outcome data.
The Bottom Line
One published animal study directly measured telomere length as an outcome of reishi triterpenoid administration, finding preservation of telomere length in aging mouse brains alongside cognitive protection and sphingolipid metabolism normalization. A 2008 cancer cell study showed Ganoderma modulates telomerase activity. A 2025 Nature Communications study identified ganoderic acid A as a senotherapeutic that extends healthspan comparably to rapamycin through ribosome homeostasis maintenance. No human clinical trial has measured reishi's effect on telomere length. The mechanistic connection is plausible and the preclinical evidence is coherent, but human data does not yet exist.
Frequently Asked Questions
Sources & References
- 1RTHM-01468·Zeng, Miao et al. (2021). “Long-Term Administration of Triterpenoids From Ganoderma lucidum Mitigates Age-Associated Brain Physiological Decline via Regulating Sphingolipid Metabolism and Enhancing Autophagy in Mice..” Frontiers in aging neuroscience.Study breakdown →PubMed →↩
- 2RTHM-00282·Yuen, John W M et al. (2008). “Telomerase-associated apoptotic events by mushroom ganoderma lucidum on premalignant human urothelial cells..” Nutrition and cancer.Study breakdown →PubMed →↩
- 3RTHM-02066·Chen, Li et al. (2025). “High-content screening identifies ganoderic acid A as a senotherapeutic to prevent cellular senescence and extend healthspan in preclinical models..” Nature communications.Study breakdown →PubMed →↩
- 4RTHM-00926·Wang, Jue et al. (2017). “Emerging Roles of Ganoderma Lucidum in Anti-Aging..” Aging and disease.Study breakdown →PubMed →↩
- 5RTHM-01417·Peng, Hsin-Hsin et al. (2021). “Ganoderma lucidum stimulates autophagy-dependent longevity pathways in Caenorhabditis elegans and human cells..” Aging.Study breakdown →PubMed →↩